Related Experiment Videos
Molecular forms of the estrogen receptor in breast cancer
1Laboratoire J.-C. Heuson de Cancérologie Mammaire 1, Institut Jules Bordet, Service de Médecine Interne, rue héger-Bordet, 1-1000 Brussels, Belgium. lcanmamm@ulb.ac.be
Abstract:
Estrogen receptors (ERs) of which two isoforms have been identified (alpha and beta) are subjected to phosphorylation, glycozylation, ubiquitination and other post-transcriptional conformational changes giving rise to a very high molecular heterogeneity. Partial proteolysis of these receptors, as well as their high tendency to associate within oligomeric structures, reinforces this property. Investigations demonstrated that this heterogeneity is not a biochemical artefact suggesting some biological relevance. Our purpose was to review this topic, especially with regard to ERalpha from breast cancers.
Insights
Estrogen receptors (ERs) exhibit significant molecular heterogeneity due to post-transcriptional modifications and oligomerization. This complex ERalpha heterogeneity in breast cancer is biologically relevant and warrants further investigation.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Estrogen receptors (ERs), specifically ERalpha and ERbeta, undergo extensive post-transcriptional modifications.
- These modifications, including phosphorylation and ubiquitination, lead to significant molecular heterogeneity.
- Receptor association into oligomeric structures further contributes to this heterogeneity.
Purpose of the Study:
- To review the molecular heterogeneity of estrogen receptors.
- To focus on ERalpha heterogeneity in the context of breast cancer.
Main Methods:
- Literature review of post-transcriptional modifications of ERs.
- Analysis of studies investigating ER heterogeneity in breast cancer.
Main Results:
- ER heterogeneity is not an artifact but possesses biological relevance.
- ERalpha exhibits substantial molecular diversity in breast cancer.
Conclusions:
- The complex heterogeneity of ERalpha is a critical factor in breast cancer.
- Understanding ER heterogeneity is essential for targeted breast cancer therapies.